SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$99.04
−0.23%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 8.94x
- Price / sales
- 103.94x
- Price / cash flow
- -37.73x
Enterprise value
- Enterprise value
- $8.5B
- EV / sales
- 93.71x
- EV / EBITDA
- -30.28x
- EV / EBIT
- -33.90x
- Market cap
- $9.4B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Sep 1, 2026